Key points from article :
A clinical trial of nicotinamide mononucleotide (NMN) concluded that NMN is safe for humans.
Investigated the safety of a single NMN dose in 10 healthy men between 40 to 60 years.
Aim of the study was to establish safety and tolerability at the dosage used.
This trial was not large enough to demonstrate efficacy of NMN.
Next step is to investigate the efficacy, suitable dosage and frequency in a larger study population.
Research by Keio University School of Medicine in Japan, published in Endocrine Journal.
